SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001140361-21-018871
Filing Date
2021-05-26
Accepted
2021-05-26 17:20:16
Documents
4
Period of Report
2021-05-20
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K brhc10025183_8k.htm 8-K 33825
2 EXHIBIT 10.1 brhc10025183_ex10-1.htm EX-10.1 232166
3 EXHIBIT 10.2 brhc10025183_ex10-2.htm EX-10.2 80621
4 EXHIBIT 10.3 brhc10025183_ex10-3.htm EX-10.3 165295
  Complete submission text file 0001140361-21-018871.txt   513581
Mailing Address 140 58TH STREET, BUILDING A SUITE 2100 BROOKLYN NY 11220
Business Address 140 58TH STREET, BUILDING A SUITE 2100 BROOKLYN NY 11220 (212) 582-1199
Brooklyn ImmunoTherapeutics, Inc. (Filer) CIK: 0000748592 (see all company filings)

IRS No.: 311103425 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-11460 | Film No.: 21967466
SIC: 2834 Pharmaceutical Preparations